Neurology Central

Esketamine receives US FDA approval for treatment-resistant depression

The US FDA (MD, USA) has recently approved a new antidepressant termed, Spravato™ (esketamine) nasal spray, along with an oral antidepressant, for treatment-resistant depression in adults.

Spravato is the first major new depression treatment to be approved by the FDA since Prozac hit the market more than 30 years ago, according to a report from the NPR.

People are considered to have treatment-resistant depression if they have tried at least two antidepressant treatments in an episode, for an adequate duration with an adequate dose, but have not responded to the treatment.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.